Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis.
Sajiir H, Keshvari S, Wong KY, Borg DJ, Steyn FJ, Fercher C, Taylor K, Taylor B, Barnard RT, Müller A, Moniruzzaman M, Miller G, Wang R, Fotheringham A, Schreiber V, Sheng YH, Hancock JL, Loo D, Burr L, Huynh T, Lockett J, Ramm GA, Macdonald GA, Prins JB, McGuckin MA, Hasnain SZ.
Sajiir H, et al. Among authors: prins jb.
Nat Commun. 2024 May 29;15(1):4528. doi: 10.1038/s41467-024-48317-x.
Nat Commun. 2024.
PMID: 38811532
Free PMC article.